Semotiadil improves survival of rats with monocrotaline-induced pulmonary hypertension: Comparison with diltiazem

European Journal of Pharmacology

Volumn 295, Issue 2-3, 1996, Pages 229-234

  Takahashi, Takashi ^a   Kanda, Tsugiyasu ^a   Imai, Susumu ^a   Suzuki, Tadashi ^b   Kobayashi, Isao ^a   Murata, Kazuhiko ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Coll of Medical Care and Technology ^*  (Japan)

Author keywords

Media thickening; Pulmonary hypertension; Right; Semotiadil; Ventricular hypertrophy

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; MONOCROTALINE; NEW DRUG; SESAMODIL FUMARATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE MASS; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SURVIVAL; TUNICA MEDIA; VASCULAR SMOOTH MUSCLE;

EID: 0030068038     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00665-6     Document Type: Article

References (20)

1. Cassis, L.A., P.E. Rippetoe, E.E. Soltis, D.J. Painter, R. Fitz and M.N. Gillespie, 1992, Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (Dup 753), a nonpeptide angiotensin type 1 receptor antagonist, J. Pharmacol. Exp. Ther. 262, 1168.
2. Dresdale, D.T., M. Schultz and R.J. Michtom, 1951, Primary pulmonary hypertension. I. Clinical and hemodynamic study, Am. J. Med. 11, 686.
3. Farhat, M.Y., M.F. Chen, T. Bhatti, A. Iqbal, S. Cathapermal and P.W. Ramwell, 1993, Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats, Br. J. Pharmacol. 110, 719.
4. Grossman, W. and E. Braunwald, 1992, Pulmonary hypertension, in: Heart Disease, ed. E. Braunwald (W.B. Saunders, Philadelphia, PA) p. 790.
5. Kageyama, M., K. Nishimura, T. Takada, N. Miyawaki and H. Yamauchi, 1991, SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs, J. Cardiovasc. Pharmacol. 17, 102.
6. Kambara, H., K. Fujimoto, A. Wakabayashi and C. Kawai, 1981, Primary pulmonary hypertension: beneficial therapy with diltiazem, Am. Heart J. 101, 230.
7. Meyrick, B. and L. Reid, 1979, Development of pulmonary arterial changes in rats fed Crotalaria spectabilis, Am. J. Pathol. 94, 37.
8. 2+ antagonist, in isolated guinea pig and rabbit hearts, J. Cardiovasc. Pharmacol. 16, 769.
9. Miyawaki, N., T. Furuta, T. Shigei, H. Yamauchi and T. Iso, 1991, Cardiovascular characterization of SD-3211, a novel benzothiazine calcium channel blocker, in isolated rabbit hearts, Life Sci. 48, 1903.
10. Nishimura, K., N. Miyawaki, H. Yamauchi and T. Iso, 1990, Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscles and cardiac muscles, Arzneim.-Forsch. 40, 244.
11. Rich, S., E. Kaufmann and P.S. Levy, 1992, The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension, New Engl. J. Med. 327, 76.
12. Senda, Y., H. Tohkai, M. Kimura, Y. Shida, S. Tsutsumi, H. Koshiyama, T. Tanaka, Y. Shimaji and T. Nogita, 1990, ECG-gated cardiac scan and echocardiographic assessments of left ventricular hypertrophy: reversal by 6-month treatment with diltiazem, J. Cardiovasc. Pharmacol. 16, 298.
13. Singh, B.N., S. Baky and K. Nademanee, 1985, Second-generation calcium antagonists: search for greater selectivity and versatility, Am. J. Cardiol. 55, 214B.
14. Stanbrook, H.S., K.G. Morris and I.F. McMurtry, 1984, Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists, Am. Rev. Respir. Dis. 130, 81.
15. Taira, N., 1987, Differences in cardiovascular profile among calcium antagonists, Am. J. Cardiol. 59, 24B.
16. Takada, T., N. Miyawaki, M. Kageyama, K. Matsuno, N. Ishida, H. Yamauchi and T. Iso, 1991, Antihypertensive effect of a novel calcium antagonist, SD-3211, in experimental hypertensive rats, J. Cardiovasc. Pharmacol. 18, 855.
17. Takahashi, T., T. Kanda, S. Imai, T. Suzuki and K. Murata, 1994, The beneficial effect of semotiadil on the development of right ventricular hypertrophy and medial proliferation in pulmonary arteries induced by monocrotaline in rats: comparison with diltiazem, Eur. Heart J. 15 (Abstr. Suppl.), 523 (abstract 2870).
18. Teramoto, N., 1993, Mechanisms of the inhibitory action of semotiadil fumarate, a novel Ca antagonist, on the voltage-dependent Ca current in smooth muscle cells of the rabbit portal vein, Jpn. J. Pharmacol. 61, 183.
19. Wilson, D.W., H.J. Segall, L.C. Pan, M.W. Lame, J.E. Estep and D. Morin, 1992, Mechanisms and pathology of monocrotaline pulmonary toxicity, Crit. Rev. Toxicol. 22, 307.
20. Young, T.E., B.S. Lundquist, E. Chester and E.K. Weir, 1983, Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension, Am. J. Cardiol. 51, 195.